-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $230

Benzinga·12/10/2025 13:04:51
Listen to the news
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $220 to $230.